Arecor Therapeutics PLC TETRIS PHARMA LAUNCHES OGLUO(R) IN GERMANY (8076E)
November 01 2022 - 3:00AM
UK Regulatory
TIDMAREC
RNS Number : 8076E
Arecor Therapeutics PLC
01 November 2022
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
TETRIS PHARMA LAUNCHES OGLUO (R) IN GERMANY
Cambridge, UK, 1 November 2022: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical company advancing today's therapies to
enable healthier lives, announces that subsidiary company, Tetris
Pharma Ltd has today launched Ogluo(R) (glucagon prefilled
autoinjector pen) as a treatment for severe hypoglycaemia in
children and adults living with diabetes in Germany. Germany is a
significant diabetes market and represents the first launch of
Ogluo(R) in the European Union.
See full Tetris Pharma announcement below:
Tetris Pharma launches Ogluo(R) in Germany
A new treatment option for severe hypoglycaemia for children and
adults living with diabetes
Represents Tetris Pharma's first launch in European Union
1 November 2022 - Tetris Pharma Ltd ("Tetris Pharma" or "the
Company"), a subsidiary of biopharmaceutical company, Arecor
Therapeutics plc (AIM: AREC), today announces the launch of
Ogluo(R) (glucagon prefilled autoinjector pen) in Germany as a
treatment for severe hypoglycaemia in children and adults living
with diabetes.
Ogluo(R) is a ready-to-use, ambiently stored, preparation of
glucagon that has been specifically designed for patients living
with diabetes with severe hypoglycaemia. There are an estimated 6.2
million adults living with diabetes in Germany (IDF Atlas 10(th)
Edition).
Ogluo(R) pricing has today been published in the LAUER-TAXE(R),
the reference for all German pharmacies, insurers, and wholesalers.
Full prescribing information can be found here. Today's launch in
Germany builds on the roll-out of Ogluo(R) in Great Britain. As
part of the pan-European commercialisation programme, Tetris Pharma
intends to commercialise Ogluo(R) in core European markets. The
Company is currently in discussions with various health authorities
across Europe to ensure timely launches in other major European
countries.
Prof. Barbara Ludwig, Universitätsklinikum Carl Gustav Carus.
Dresden, commented:
" The risk of severe hypoglycaemia can be frightening for people
living with diabetes, as well as for family, friends and carers.
With Ogluo(R) being made available in Germany, it gives people
living with diabetes another ready-to-use option."
Dr Shafiq Choudhary, Managing Director of Tetris Pharma,
commented:
"With the launch of Ogluo(R) in Germany, Tetris Pharma has
achieved a significant milestone through the commercialisation of
our flagship product. A severe hypoglycaemic event can be very
frightening, not only for the patients, but for those around them
who have to act quickly. The launch of Ogluo(R) means that patients
living with diabetes in Germany who may experience severe
hypoglycaemia will now have a new option to tackle those events. We
look forward to expanding our reach within Europe over the coming
months to bring this new treatment to people living with
diabetes."
Enquiries:
Tetris Pharma
Shafiq Choudhary +44 (0)1628 337579
Notes to Editors
Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a
commercial-stage specialty pharmaceutical company with expertise in
registering, marketing, sales and the distribution of speciality
hospital products across the UK and Europe. Our experienced team
has a proven history of building and growing sales. Having secured
distribution rights for already licensed products across Europe, we
have a portfolio of niche injectable products including Ogluo(R) ,
a ready-to-use glucagon for emergency use to treat hypoglycaemia.
We collaborate with partners to provide patients with effective
treatments and quality healthcare by ensuring we deliver
accountability, partnership and performance.
For further information, please visit tetrispharma.com
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner, David Daley, Angela Email: arecor@consilium-comms.com
Gray
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PRLMBBRTMTIJBMT
(END) Dow Jones Newswires
November 01, 2022 03:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024